Y
Yinghui Wang
Researcher at Seattle Genetics
Publications - 19
Citations - 832
Yinghui Wang is an academic researcher from Seattle Genetics. The author has contributed to research in topics: Brentuximab vedotin & Cutaneous T-cell lymphoma. The author has an hindex of 8, co-authored 18 publications receiving 628 citations.
Papers
More filters
Journal ArticleDOI
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial
H. Miles Prince,H. Miles Prince,Youn H. Kim,Steven M. Horwitz,Reinhard Dummer,Julia Scarisbrick,Pietro Quaglino,Pier Luigi Zinzani,Pascal Wolter,Jose A Sanches,Pablo L. Ortiz-Romero,Oleg E. Akilov,Larisa J. Geskin,Larisa J. Geskin,Judith Trotman,Kerry Taylor,Stéphane Dalle,Michael Weichenthal,Jan Walewski,David E. Fisher,Brigitte Dréno,Rudolf Stadler,Tatyana Feldman,Timothy M. Kuzel,Yinghui Wang,Maria Corinna Palanca-Wessels,Erin Zagadailov,William L. Trepicchio,Wenwen Zhang,H. Lin,Yi Liu,Dirk Huebner,Meredith Little,Sean Whittaker,Madeleine Duvic,David Joske,Ian D. Lewis,Constanze Jonak,Franz Trautinger,Oliver Bechter,Dominique Bron,Vladmir Cláudio Cordeiro de Lima,José Antonio Sanches,Richard Klasa,Martine Bagot,Marie Beylot-Barry,Michel D'Incan,Florent Grange,Jan P. Nicolay,Marion Wobser,Chalid Assaf,Carmen Loquai,Michele Spina,Alberto Bosi,Pier Paolo Fattori,Aleksandra Grzanka,Andres Lopez-Hernandez,Jose Juan Rifon Roca,Silvana Novelli Canales,Timothy M Illidge,Rod Johnson,Stephen Morris,Pam McKay,O. Akilov,Steve Horwitz,Barbara Pro,Timothy Kuzel,Adam Lerner,Herbert Eradat,Lubomir Sokol,David C. Fisher,Sarah Hughey +71 more
TL;DR: Significant improvement in objective response lasting at least 4 months was seen with brentuximab vedotin versus physician's choice of methotrexate or bexarotene in previously treated patients with CD30-positive cutaneous T-cell lymphomas.
Journal ArticleDOI
Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma.
Ann S. LaCasce,R. Gregory Bociek,Ahmed Sawas,Paolo Caimi,Edward Agura,Jeffrey Matous,Stephen M. Ansell,Howland E. Crosswell,Miguel Islas-Ohlmayer,Caroline Behler,Eric C. Cheung,Andres Forero-Torres,Julie M. Vose,Owen A. O'Connor,Neil C Josephson,Yinghui Wang,Ranjana H. Advani +16 more
TL;DR: BV plus bendamustine as first salvage therapy in relapsed/refractory HL is highly active with a manageable toxicity profile and a protocol amendment requiring premedication reduced IRR severity.
Journal ArticleDOI
Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older
Andres Forero-Torres,Beata Holkova,Jerome H. Goldschmidt,Robert T. Chen,Gregg Olsen,Ralph V. Boccia,Rodolfo Bordoni,Jonathan W. Friedberg,Jeff P. Sharman,Maria Corinna Palanca-Wessels,Yinghui Wang,Christopher A. Yasenchak +11 more
TL;DR: Brentuximab vedotin monotherapy may provide a frontline treatment option for older patients who cannot tolerate conventional combination chemotherapy for Hodgkin lymphoma, and preliminary data showed no substantial age-related changes in brentuxo-vedotin pharmacokinetics.
Journal ArticleDOI
Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged ≥60 years with HL
Jonathan W. Friedberg,Andres Forero-Torres,Rodolfo Bordoni,Vivian Jean M. Cline,Dipti Patel Donnelly,Patrick J. Flynn,Gregg Olsen,Robert T. Chen,Abraham P. Fong,Yinghui Wang,Christopher A. Yasenchak +10 more
TL;DR: For elderly patients with HL, BV plus DTIC may be a frontline option based on tolerability and response duration, but despite activity, Bv plus bendamustine is not a tolerable regimen in these patients.
Proceedings ArticleDOI
Abstract PD1-06: Open label phase 1b/2 study of ladiratuzumab vedotin in combination with pembrolizumab for first-line treatment of patients with unresectable locally-advanced or metastatic triple-negative breast cancer
Hyo S. Han,Sami Diab,Carlos Alemany,Reva Basho,Ursa Brown-Glaberman,Jane L. Meisel,Timothy J. Pluard,Javier Cortes,Patrick M. Dillon,Johannes Ettl,Sherko Kuemmel,Luis Sanchez,Mafalda Oliveira,Joyce O'Shaughnessy,Steven W. Papish,Rajni Sinha,Danielle Sterrenberg,Erica Stringer-Reasor,Michaela Tsai,Rafael Villanueva Vazquez,Rachel Wuerstlein,Yinghui Wang,Zejing Wang,Valentina Boni +23 more
TL;DR: LV + pembrolizumab (pembro) may result in complementary, as well as synergistic, activity through LV-induced ICD that creates a microenvironment favorable for enhanced anti-PD-(L)1 activity.